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Abstract
Radioligands for DAT and VMAT2 are widely used presynaptic markers for assessing dopamine (DA) nerve terminals in
Parkinson disease (PD). Previous in vivo imaging and postmortem studies suggest that these transporter sites may be
regulated as the numbers of nigrostriatal neurons change in pathologic conditions. To investigate this issue, we used in vitro
quantitative autoradioradiography to measure striatal DAT and VMAT2 specific binding in postmortem brain from 14
monkeys after unilateral internal carotid artery infusion of 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine (MPTP) with doses
varying from 0 to 0.31 mg/kg. Quantitative estimates of the number of tyrosine hydroxylase (TH)-immunoreactive (ir)
neurons in substantia nigra (SN) were determined with unbiased stereology, and quantitative autoradiography was used to
measure DAT and VMAT2 striatal specific binding. Striatal VMAT2 and DAT binding correlated with striatal DA (rs=0.83,
rs=0.80, respectively, both with n=14, p,0.001) but only with nigra TH-ir cells when nigral cell loss was 50% or less
(r=0.93, n=8,p=0.001 and r=0.91, n=8,p=0.002 respectively). Reduction of VMAT2 and DAT striatal specific binding sites
strongly correlated with each other (r=0.93, n=14, p,0.0005). These similar changes in DAT and VMAT2 binding sites in the
striatal terminal fields of the surviving nigrostriatal neurons demonstrate that there is no differential regulation of these two
sites at 2 months after MPTP infusion.
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Introduction
Selective degeneration of dopaminergic neurons in the substan-
tia nigra pars compacta (SNpc) combined with striatal DA
deficiency produces the major motor manifestations of idiopathic
PD [1,2]. Reduction of dopaminergic neurons in PD patients and
animal models of parkinsonism leads to substantial loss of the pre-
synaptic markers DAT, TH and VMAT2. However, there are
discrepancies in the magnitude of the changes in these presynaptic
markers, and differential regulation of these sites may account for
these discrepancies [3–5].
Previous studies have used in vitro or in vivo methods to measure
the effects of nigrostriatal deficiency on loss of striatal DAT and
VMAT2. One in vitro autoradiographic study from PD patients
revealed greater striatal loss of DAT than VMAT2 specific binding
sites [3]. However, studies with MPTP-treated rodents have
produced conflicting data on the extent of reduction of striatal
DAT and VMAT2. Some studies reported greater loss of striatal
DAT compared to VMAT2 [4], whereas others reported no
significant difference in loss of these specific binding sites [6]. In vivo
radiotracer imaging studies of VMAT2 and DAT have revealed
conflicting results as well. Some report greater loss of striatal DAT
[5] while others found greater loss of VMAT2 in PD patients [7]. In
addition, there are discrepancies in nonhuman primate models of
PD [8] with variable changes in DAT and VMAT2 loss [8–10].
A number of factors complicate interpretation of data from
human studies including studying subjects at different clinical
stages of disease, disparities in length of drug treatment and
differences in radiotracer specificity. Animal models of PD have
been used to overcome many of these problems; however,
differences in experimental methodology including limited range
of severity of neurotoxin-induced neuronal loss, varying specificity
of radioligands and insufficient time after neurotoxin delivery to
achieve a stable course may account for varying results.
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changes of DAT and VMAT2 binding sites in adult male monkeys
who had no other exposure to experimental drugs after unilateral
internal carotid artery infusion of MPTP with doses varying from
0 to 0.31 mg/kg. This infusion schedule produced a wide range of
severity of unilateral stable hemi-parkinsonism while minimizing
exposure of the contralateral hemisphere to MPTP [11–13].
[
3H]WIN 35,428 was chosen to label DAT [14] and (+)-[
3H]
dihydrotetrabenazine (DTBZ) was used for VMAT2 [15,16]. This
experimental design permitted comparison of changes in DAT
and VMAT2 binding sites in a full spectrum of nigrostriatal
neuronal loss induced by MPTP. Finally, we also determined the
relationship of DAT and VMAT2 binding to stereologic counts of
nigral neurons and striatal DA.
Methods
Ethics Statement
We used the minimum number of animals necessary for this
research and followed all relevant national and international
guidelines. In accordance with the recommendations of the
Weatherall report ‘‘The use of non-human primates in research,’’
we took all steps to ameliorate suffering in our work with non-
human primates. The welfare of the animals conformed to the
requirements of National Institutes of Health (NIH), and we
followed the guidelines prescribed by the NIH Guide to
Laboratory Animal Care. This work was conducted at the
Nonhuman Primate Facility of Washington University in St.
Louis with approval from its Institutional Animal Care and Use
Committee (IACUC). The protocol number is 20110161, last
approved on 8 July 2011. All animals were housed in the same
room in cages meeting or exceeding the stipulated size
requirements. Animals were maintained in facilities with 12-hour
dark and light cycles, given access to foold and water ad libitum;
all animals were equally engaged with a variety of psychologically
enriching tasks such as watching movies or playing with
appropriate toys. No animal was knowingly exposed to potential
infection. Humane endpoints were pre-defined in this protocol and
applied as a measure if necessary to reduce any discomfort.
Subjects
Fourteen male macaques (Macaca fascicularis and Macaca
nemestrina), between the ages of 3.5 and 6.5 years old
(mean=5.461.0), served as subjects.
MPTP infusion
MPTP (Sigma, St. Louis, MO) was administered as described
by Tabbal et al., [13]. A single MPTP dose of 0 (normal saline
with no MPTP) to 0.31 mg/kg was infused into the right internal
carotid artery. Location was confirmed through angiograms before
and after MPTP infusion [17]. After the procedure, animals were
continuously observed until able to care for themselves. Animals
received no dopaminergic drugs at any time.MPTP and
potentially toxic metabolites were decontaminated and discarded
as follows. At the end of the MPTP infusion, all work surfaces and
equipment were decontaminated immediately with a 2.5%
solution of hypochlorite bleach; any unwanted remaining solution
of MPTP, plastic products (syringes, tubing, etc.), and dry waste
were treated with bleach, and disposed as hazardous chemical
waste through Washington University in St. Louis Environment,
Health and Safety (EHS) chemical waste disposal program. After
administration of MPTP, trained staff lined the base of the cage
and the drop pan with plastic-backed absorbent pads; sprayed
these pads and drop pans with bleach, allowed them to soak for
10 min, then disposed this biohazardous waste daily for 5 days
post MPTP.
Tissue Processing
The monkeys were euthanized two months after MPTP infusion
with a lethal overdose of pentobarbital (100 mg/kg, i.v.) (Butler
Schein Animal Health, Dublin, OH). The brains were removed
within 10 minutes, and the hemispheres and midbrain were
separated. Standard punch biopsies were taken from caudate and
putamen, quickly frozen on dry ice snow and saved at 280uC for
DA and DA metabolite quantification. A coronal slab from each
hemisphere was rapidly frozen in liquid nitrogen vapor and then
stored at 280uC for autoradiography. Coronal sections, 20 mm
thick, were cut on a cryostat (Microm HM 550 series, Thermo
Fisher Scientific Inc, Waltham, MA), mounted on superfrost plus
glass slides (Thermo Fisher Scientific, Waltham, MA), and stored
at 280uC until used in quantitative autoradiography. The entire
midbrain was post-fixed for 7 days in 4% paraformaldehyde in
0.1 M phosphate-buffered saline (PBS) before transfer to 30%
sucrose for 7 days, and then cut on a freezing microtome into
serial, free-floating 50 mm-thick transverse sections. A random
series of every 6
th section was processed for TH immunocyto-
chemistry.
TH Immunohistochemistry
We used TH-immunostaining to identify dopaminergic neu-
rons. Sections were treated for 20 minutes in 0.3% hydrogen
peroxide (Fisher Scientific, Fair Lawn, NJ), washed 3 times in PBS,
and blocked in PBS with 2% normal goat serum and 0.3% Triton
X-100 for 2 hours prior to overnight incubation at 4uC with rabbit
anti-TH (1:1000; Chemicon International, Inc., Temecula, CA) .
After washes with PBS (5 min, 3 times), the sections were reacted
at room temperature for 60 minutes with biotin-conjugated
universal secondary antibody provided in Universal Vectastain
(1:200; Vector Laboratories, Burlingame, CA). After subsequent
washes in PBS, the sections were incubated in streptavidin-biotin
complex (Vector Laboratories, Burlingame, CA) for 60 min at
room temperature. Following thorough rinsing with PBS, staining
was visualized by incubation in 3, 39-diaminobenzidine solution
with nickel enhancement (Vector Laboratories, Burlingame, CA).
After immunostaining, floating tissue sections were mounted on
gelatin-coated glass slides and counterstained with cresyl violet.
Sections without primary antibody served as negative controls.
Unbiased stereologic counting of nigrostriatal neurons
We applied unbiased stereology to the immunostained sections
to quantify the number of dopaminergic neurons. Procedures
followed those defined by Gunderson, et al., [18,19] using an
Olympus BX41 Microscope with a proscan stage kit and DP70
digital camera. The SN was defined as the region ventral to the
medial leminiscus, dorsal to the cerebral peduncle and lateral to
the third cranial nerve (Figure 1). The computer-assisted
stereology (CAST, version 3.2.10.0; Visiopharm, Hoersholm,
Denmark) was utilized to achieve a random sampling of 5.22%
(frame length/step length) of the total region of interest area with
an 80680 mm
2 counting frame and height of 22 mm with a 3 mm
top guard zone. TH-ir cells were identified; total tissue thickness
ranged from 25 to 30 mm due to shrinkage during processing.
Weighted thickness averaging was applied to the calculations to
compensate for differences in tissue thickness. An injected/control
No Differential Regulation of DAT and VMAT2
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31439ratio was calculated for cell number to control for any possible
differences in staining intensity/antibody penetration between the
different animals and inter-subject variability.
Quantitative autoradiography
Tissue preparation for [
3H] DTBZ autoradiogra-
phy. Procedures were adapted from Frey K et al., [20].
Thawed tissue sections were pre-incubated for 5 minutes at
25uC in potassium phosphate buffer with EDTA at pH 8.0 and
then incubated for 30 minutes at 25uC in potassium phosphate
buffer containing 7 nM (+)-[
3H] DTBZ (American Radiolabled
Chemicals, Inc., St. Louis, MO; specific activity 20 Ci/mmol) in
the presence (nonspecific binding) or absence (total binding) of
10 mM unlabeled ‘‘cold’’ tetrabenazine. Sections were rinsed 3
times in fresh potassium phosphate buffer and once briefly in
distilled water at 4uC to remove buffer salts. The slides were air-
dried overnight and analyzed on a Beta Imager (BioSpace, Paris,
France) for 24 hours in the presence of [
3H] standards (American
Radiolabled Chemicals, Inc., St. Louis, MO).
Tissue preparation for [
3H] WIN 35,428 autoradiogra-
phy. Tissue sections were pre-incubated for 20 min at 4uCi n
phosphate buffer with EDTA at pH 7.4. Sections were then
incubated for 1 hr at 4uC in buffer containing 5 nM [
3H] WIN
35,428 (New England Nuclear/Perkin Elmer, Boston, MA;
specific activity 85.9 Ci/mmol) in the presence (nonspecific
binding) or absence (total binding) of 10 mM nomifensine (Sigma
Chemical, St. Louis, MO). Sections were rinsed twice in fresh
phosphate buffered saline at 4uC and air-dried overnight and
analyzed on a Beta Imager for 24 hours in the presence of [
3H]
standards [21].
Quantitative analysis. Quantitative analysis was performed
with the program b-Vision Plus (BioSpace, Paris, France) to
demarcate the anatomical regions of interest and measure
radiolabeled uptake in tissue in cpm/mm
2. A reference curve
was obtained with each Bioimager analysis using [
3H] standards
containing known amounts of radioactivity. This permitted
conversion of the tissue sections measures from cpm/mm
2 to
nCi/mg tissue. The specific activity of each radioligand was used
to convert these measures to femtomoles per milligram tissue.
Specific binding was determined by subtracting nonspecific
binding values from the total binding values, measured in
adjacent sections.
For [
3H] WIN 35,428 and [
3H] DTBZ, saturation binding
analyses were conducted over a range of radioligand concentra-
tions between 0.25 and 15 nM. Linear regression analysis of the
data was used to determine the equilibrium dissociation constant
(Kd) and the maximum number of binding sites (B max) using
Scatchard analysis for each radioligand. Since Kd for each
radioligand did not change between control and severely affected
tissues at the highest dose of MPTP, we subsequently used a single
concentration (5 nM for [
3H] WIN 35,428 and 7 nM for [
3H]
DTBZ) that was about 3 times the Kd of [
3H] WIN 35,428
(1.5 nM) and of [
3H] DTBZ (2.7 nM). We then could calculate
Bmax from these data having demonstrated that Kd remained
constant.
Quantification of DA
Striatal level of DA was measured using high performance
liquid chromatography with electrochemical detection (HPLC-
EC) [22]. The HPLC system consisted of an ESA Coulochem III
electrochemical detector (ESA, Dionex Company, Chelmsford,
MA) with ESA model 584 HPLC pump. The conditioning cell was
ESA model 5021A set at 2450 mV, and the microdialysis cell was
model 5014B set at 400 mV. The optimal electrode potentials for
each compound were determined by current-voltage curves.
Sample preparation consisted of homogenizing the previously
frozen striatal tissue in glass homogenizers on ice in 450 ul of cold
0.1 M perchloric acid containing 0.4 mM sodium metabisulfite,
0.1 mM ethylenediaminetetraacetic acid (EDTA) and 50 ml of 3,4
dihydroxybenzylamine as an internal standard. The samples were
centrifuged for 10 minutes at 15006 ga t4 uC. The supernatant
was filtered using a 0.22 micron filter spun at 15,0006 g for
5 minutes and 20 ml of the filtrate was injected onto the HPLC for
analysis. The internal standard permitted quantification of DA.
The values were expressed as ng/gm of brain tissue.
Statistical analysis
Results were analyzed using SPSS for Windows, version 18.0.2
(IBM, Chicago. IL). All in vitro measures of VMAT2 Bmax, DAT
Bmax, SN cell counts and striatal DA were expressed as a ratio
between the values obtained on the MPTP lesioned side and that
of the contralateral side (injected/control side) to minimize the
effect of biological variability among animals. We compared the
residual binding density of VMAT2 and DAT with Wilcoxon
signed ranks test since these data were not normally distributed
demonstrated by Shapiro-Wilks test of normality [23]. The
relationships of VMAT2 Bmax, DAT Bmax, and striatal DA
among each other and to nigral cell counts were determined with
Spearman correlations due to a non-normal distribution of data
with some clustering near zero in severely affected animals. In a
separate analysis, we excluded the clustered data to permit analysis
with Pearson correlations in the remaining 8 monkeys. A two-
tailed P value of less than 0.05 was considered significant.
Results
All 14 monkeys completed the study protocol successfully and
were euthanized at 56 to 60 days after MPTP infusion. Animals
were always able to care for themselves despite not receiving any
anti-parkinsonian drugs for the duration of the study. Animals
manifested a wide range of severity of parkinsonism from none in
controls to severe unilateral parkinsonism with the highest doses of
MPTP.
Striatal DAT and VMAT2 and nigral DA neuron
distribution in control and MPTP-treated brain
We performed DAT and VMAT2 autoradiography in brain
tissue from all animals. The binding patterns of [
3H] WIN 35,428
reflecting DAT and [
3H] DTBZ reflecting VMAT2 control
animals appeared consistent with previous reports in monkey and
human brain. [24–27] (Figure 2A and E). The dorsal portions of
Figure 1. SN outlined on a TH-immunostained transverse slice
with 26 magnification. Typical pictures were taken on the left (A)
and right (B) side of the same slice separately with SN and ventral
tegmental area (VTA) outlined. SN lies ventral and lateral to VTA. The 3
rd
cranial nerve fibers are indicated by arrows. Scale bar: 1 cm.
doi:10.1371/journal.pone.0031439.g001
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densities, whereas ventral striatal regions, including the nucleus
accumbens, displayed lower binding densities. The general striatal
binding patterns of the two radioligands in MPTP treated
monkeys also appeared similar to that of controls (Figure 2 B–D
and F–H) although the specific binding densities were variably
reduced. Nonspecific binding was minimal for both radioligands
(,10% of total binding).
We utilized stereology to quantify TH-ir neuron count in SNpc
in 13 monkeys. One animal was excluded from the nigral cell
count measures since the nigral tissue was damaged during
processing. The distribution of TH-ir SNpc neurons did not
appear to change as a function of MPTP dose, although the
number of TH-ir SNpc neurons decreased.
Relationship between VMAT2 and DAT binding density
and SNpc TH neurons
Examination of the distribution of the data in Figure 3 reveals a
flooring effect for the VMAT2 and DAT binding density in
animals with more than 50% nigral cell loss. Excluding those
animals with more than 50% nigral cell loss revealed a significant
correlation between the cell count ratio and Bmax ratio (injected/
control side) for VMAT2 and DAT in the remaining animals
(r=0.93, n=8,p=0.001and r=0.91, n=8,p=0.002 respectively).
Correlation between VMAT2 and DAT binding density
and striatal DA
Six animals with greater than 50% neuronal cell loss had near
zero striatal dopamine measures similar to their striatal VMAT2
and DAT specific binding. The data from the other 8 animals had
a broad distribution permitting a Pearson correlation analysis
despite clustering of the other values near zero. There was a strong
significant correlation between residual striatal DA and VMAT2
as well as with DAT specific binding with or without the 6
clustered data points. (Spearman’s correlation with all data:
rs=0.83, n=14, p,0.0005 and rs=0.80, n=14, p=0.001
respectively; Pearson’s correlation without the clustered points:
r=0.94, n=8,p=0.001 and r=0.95, n=8,p,0.0005 respectively)
(Figure 4).
Similar loss of the DAT and VMAT2 binding after MPTP
treatment
The loss of striatal DAT and VMAT2 binding sites was similar
following a wide range of MPTP doses and was not statistically
different from each other (Wilcoxon signed ranks test
z(14)=20.089, p=0.93). There was a strong, significant correla-
tion between Bmax of VMAT2 and DAT with or without the data
clustered near zero (Spearman’s correlation with all data: rs=0.93,
n=14, p,0.0005; Pearson’s correlation without the clustered
points: r=0.98, n=8,p,0.0005) (Figure 5).
Discussion
The present study demonstrates that DAT and VMAT2
striatal binding sites do not have differential regulation across a
wide range of nigral cell loss. Our data differ from the findings of
postmortem studies in PD patients [3], which report greater loss
of striatal DAT than VMAT2 radioligand binding. In vivo studies
with molecular imaging methods such as positron emission
tomography (PET) can permit direct comparisons of DAT and
VMAT2 binding. Numerous PET studies have compared some
combination of fluorine-18-L-dihydroxyphenylalanine (FD), re-
flecting aromatic amino-acid decarboxylase activity and DA
storage, a DAT and a VMAT2 radioligand in the same PD
patients [5,7,28,29] with inconsistent findings. Interpretation of
data from human studies can be complex. Differences in subject
selection criteria, the presence of other disorders, wide disparities
in length of drug exposure, limited spatial resolution of PET,
effects of postmortem delay on measures of dopamine [30,31]
and variable specificity of radioligands can all influence the
findings. It has, therefore, been difficult to discern the exact
nature of regulation of different dopaminergic markers in
humans.
Nonhuman primate models, nevertheless, have the connectivity
and structural complexity homologous to the human brain [32]
and offer significant advantages. Indeed the animal model allowed
us to make measurements of presynaptic dopaminergic markers
and neuronal counts in SNpc at different severities of nigrostriatal
injury in a more controlled manner than would be possible in
humans. In addition, the unilateral infusion strategy permitted use
of an internal control thereby minimizing the effects of inter-
subject variability. The major limitation of the MPTP model is
that MPTP pathophysiology is not identical to idiopathic PD [32].
Although there may be some similarities in mechanism of cell
death [33] (such as mitochondrial energy defects [34], free radical
damage [35]) or possibly excitotoxicity [36]; MPTP may
preferentially damage terminal fields since its toxic metabolite 1-
methyl-4-phenyl-2,3-dihydropyridium ion (MPP+) is taken up by
DA neurons via DAT [37]. However, preferential terminal loss in
striatum compared to DA cell body loss in SNpc has been
described in humans with PD [38] as well as with MPTP treated
animals [39,40]. Thus, conservatively one could view MPTP as
primarily a model of dopaminergic cell loss rather than as a model
of the pathophysiology of human PD. Nevertheless, this model is
well-suited for the purpose of this study, to investigate whether
differential regulation of DAT and VMAT2 occurs across a wide
range of degrees of dopaminergic cell loss. All animals were
subjected to the same psychologically enrichment tasks as required
for care of nonhuman primates [41]. It is unknown whether any of
the tasks that we employed could have induced neurogenesis, as
some tasks may or may not have this effect [42,43]. However, in
our animal model system such effect would not alter the
relationship between VMAT2 and DAT. Furthermore such an




3H] WIN 35,428 binding to DAT (top row) (A–D), [
3H]
DTBZ binding to VMAT2 (bottom row) (E–H) in coronal sections from
the injected side of control (A and E) and MPTP-treated monkeys (B–D
and F–H). Images represent total binding, according to the pseudo-
color bar on the right side of each image. Scale bar: 0.5 cm.
doi:10.1371/journal.pone.0031439.g002
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dependent effect of MPTP that we found.
We found a strong correlation between VMAT2 and DAT
binding densities and postmortem measures of striatal DA levels
but only with the number of SNpc dopaminergic neurons as long
as the degree of SNpc neuronal loss was limited. The correlation
with striatal DA agrees with other studies (for VMAT2 [6] and for
DAT [44]). The loss of TH-ir SNpc DA neurons correlated well
with reduction in striatal DAT and VMAT2 binding density as
long as at least 50% of nigral cells were preserved; greater loss
appears to be associated with a flooring effect for DAT or
VMAT2. This greater degree of terminal field loss exceeding
nigral cell body loss suggests that destruction of terminals fields
may precede cell body loss, but we do not have time-dependent
measures to prove this. We found no evidence consistent with
axonal sprouting containing additional DAT or VMAT2 sites that
would potentially reduce the preferential loss of terminal field
markers compared to SNpc DA cell bodies [45,46]; the
Figure 3. Relationship between VMAT2 (A) or DAT (B) Bmax and residual SNpc TH-ir neurons. The value for each monkey was expressed
as the ratio of the injected side to the control side in 13 monkeys.
doi:10.1371/journal.pone.0031439.g003
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the TH-ir fibers and terminals include increased synthesis of TH,
increased DA release and turnover, and decreased DA uptake.
Interestingly, one previous study also investigated the relation-
ship between striatal FD uptake and stereologic counts of nigral
dopaminergic neurons in animals with graded MPTP lesions [47].
That study limited analysis to those animals that had no more than
a 35% loss of nigral neurons and found a significant correlation
between FD uptake and striatal dopamine content, but no
significant correlation to nigral cell counts. The limited nigrostri-
atal injury and poor distribution of data included in that study may
contribute to the discrepancy with our study that included a wider
range of injury.
In summary, our data demonstrate no differential regulation of
striatal DAT compared to VMAT2 specific binding sites across a
wide range of severity of nigrostriatal neuronal loss in MPTP-
Figure 4. Relationship between VMAT2 (A) or DAT (B) Bmax and residual striatal dopamine content. The values for each monkey were
expressed as the ratio of the injected side to the contralateral side, and the line is the linear fit of the data.
doi:10.1371/journal.pone.0031439.g004
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tation of molecular imaging studies in humans that compare
different radiotracers of nigrostriatal neurons in disorders such as
idiopathic PD or other neurodegenerative conditions that affect
nigrostriatal pathways. Do differential results with different
radiotracers reflect differences in noise properties or biases of the
imaging techniques [48–50]; are there differential effects from
previous drug exposures or differences in timing of changes in
these different molecular targets? Our data strongly suggest that
differential regulation of these sites is not a likely cause of disparate
findings with the different radiotracers. We only examined
changes in DAT and VMAT2 at 2 months after MPTP-induced
injury; however, we previously demonstrated that the clinical
effects of the lesions in this animal model are stable for as long as
1K years [12] making it less likely that our findings would change
with longer observation times. Short-term studies, on the other
hand, could determine whether there is lack of differential
regulation earlier in the course of nigrostriatal injury as well as
whether terminal fields are damaged prior to nigral cell bodies.
This will be important for extending the applicability of these
different radiotracers as potential biomarkers of nigrostriatal
neurons.
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